Insider Buying: Renalytix Plc (LON:RENX) Insider Acquires 25,000 Shares of Stock

Renalytix Plc (LON:RENX) insider James Renwick McCullough purchased 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were bought at an average cost of GBX 9 ($0.11) per share, with a total value of £2,250 ($2,839.83).

James Renwick McCullough also recently made the following trade(s):

• On Thursday, December 5th, James Renwick McCullough acquired 53,300 shares of Renalytix stock. The shares were purchased at an average price of GBX 8 ($0.10) per share, with a total value of £4,264 ($5,381.80).

Renalytix Stock Performance

Shares of LON:RENX opened at GBX 9.15 ($0.12) on Friday. The business has a 50-day moving average of GBX 7.76 and a two-hundred day moving average of GBX 11.23. The firm has a market capitalization of £15.18 million, a PE ratio of -38.13 and a beta of 2.10. The company has a debt-to-equity ratio of 173.95, a current ratio of 0.53 and a quick ratio of 2.42. Renalytix Plc has a 12 month low of GBX 6.50 ($0.08) and a 12 month high of GBX 74.90 ($0.95).

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.